Michael Aaron Morse, MD

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address morse004@mc.duke.edu

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1993 - 1996
  • Medical Resident, Medicine, University of Washington, 1990 - 1993
  • M.D., Yale University, 1990

Grants

Publications

Clark, Joseph, Michael A. Morse, Michael K. K. Wong, David F. McDermott, Howard Kaufman, Gregory A. Daniels, Jessica C. Perritt, Hong Hua, and Sandra Aung. “Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).” In Journal of Clinical Oncology, 34:511–511. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.2_suppl.511.

Full Text

Wong, Michael K. K., Michael A. Morse, David F. McDermott, Joseph I. Clark, Howard L. Kaufman, Gregory A. Daniels, Hong Hua, and Sandra Aung. “Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2.” Trials in Progress, January 2016. https://doi.org/10.1158/2326-6074.cricimteatiaacr15-b140.

Full Text

Buchbinder, Elizabeth I., Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Sandra Aung, Howard L. Kaufman, Marc S. Ernstoff, et al. “A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.” J Immunother Cancer 4 (2016): 52. https://doi.org/10.1186/s40425-016-0155-8.

PMID
27660706
Full Text

Song, Qing-Kun, Jun Ren, Xin-Na Zhou, Xiao-Li Wang, Guo-Hong Song, Li-Jun Di, Jing Yu, et al. “The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.” Oncotarget 6, no. 38 (December 1, 2015): 41350–59. https://doi.org/10.18632/oncotarget.5534.

PMID
26462021
Full Text

Clark, Joseph I., Michael A. Morse, Michael K. K. Wong, David F. Mcdermott, Howard L. Kaufman, Gregory A. Daniels, Jessica C. Perritt, Hong Hua, and Sandra Aung. “Durability of responses in patients with metastatic renal cell carcinoma treated with high dose lnterleukin-2 (HD IL-2).” In Bju International, 116:6–6. WILEY-BLACKWELL, 2015.

Scholars@Duke

Ren, X. R., J. Wang, T. Osada, R. A. Mook, M. A. Morse, L. S. Barak, H. K. Lyerly, and W. Chen. “Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth.” Breast Cancer Res 17, no. 1 (December 2015): 528. https://doi.org/10.1186/s13058-015-0528-9.

PMID
25778364
Full Text

Calvo, Emiliano, Jose Lopez-Martin, Johanna Bendell, Joseph P. Eder, Matthew Taylor, Patrick A. Ott, M Catherine Pietanza, et al. “NIVOLUMAB (NIVO) MONOTHERAPY OR IN COMBINATION WITH IPILIMUMAB (IPI) FOR TREATMENT OF RECURRENT SMALL CELL LUNG CANCER (SCLC).” Asia Pacific Journal of Clinical Oncology 11 (November 1, 2015): 118–118.

Scholars@Duke

Antonia, S. J., J. Bendell, M. Taylor, E. Calvo, D. Jaeger, F. de Braud, P. A. Ott, et al. “Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.” In Annals of Oncology, 26:74–75. OXFORD UNIV PRESS, 2015.

Scholars@Duke

Calvo, E., J. A. López-Martin, J. Bendell, J. P. Eder, M. Taylor, P. A. Ott, M. C. Pietanza, et al. “3098 Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC).” In European Journal of Cancer, 51:S633–S633. Elsevier BV, 2015. https://doi.org/10.1016/s0959-8049(16)31739-7.

Full Text

Pages